LETTER FROM THE EDITOR - OCTOBER

 

Hello JITC Readers,

As I welcome you to the latest edition of the JITC Digest, I am excitedly looking ahead to the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs, just two weeks away, November 1st–5th, at the Convention Center in beautiful San Diego. 

There will be a number of exciting JITC events throughout the conference. For those of you attending in person, I encourage you to meet JITC’s Interim Deputy Editor-in-Chief Dr. Sjoerd H. van der Burg while he hosts a Meet-the-Editor session at the SITC booth on Saturday, November 4th at 12:15 p.m. PDT. Additionally, join me at the awards ceremony later that day at 6:30 p.m. PDT to congratulate the 2023 JITC Best Paper Award winners as well as our first class of graduates from the JITC Peer Review Mentorship Program. If you can’t make it to San Diego, be sure to follow JITC’s coverage on our LinkedIn and X social media accounts. See the special feature below for full details of all the JITC-related events at SITC 2023. 

While there will be plenty of outstanding science at the upcoming SITC meeting, there is compelling research published each month in JITC. This month’s highlights include a study by Karen Kai-Lin Fang et al on how anti-CD4-chimeric antigen receptor (CAR4) double-negative T cells (DNTs) can effectively target T-cell acute lymphoblastic leukemia and peripheral T-cell lymphoma. These findings support the potential use of allogeneic CAR4-DNTs as a novel treatment strategy for T-cell malignancies. Wenwen Zhang et al present a single-arm, phase II study that demonstrates the promising efficacy and safety of lenvatinib plus anti-PD-1 antibodies as conversion therapy in unresectable hepatocellular carcinoma. Check out these and other intriguing science stories below. 

I hope to see you all in San Diego! 

Regards,
James L. Gulley, MD, PhD, FACP
Journal for ImmunoTherapy of Cancer Interim Editor-in-Chief